Needham Reiterates Buy on Selecta Biosciences, Maintains $5 Price Target

Needham analyst Gil Blum reiterates Selecta Biosciences (NASDAQ:SELB) with a Buy and maintains $5 price target.

byBenzinga Newsdesk

March 3, 2023

1 minute read

Needham analyst Gil Blum reiterates Selecta Biosciences (NASDAQ:SELB) with a Buy and maintains $5 price target.

Harpoon Therapeutics President, CEO Jerry McMahon Resigns; Co Names Julie Eastland As President, CEO

By Benzinga Newsdesk

Today, 3:34 PM

Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Julie Eastland has been named President and Chief Executive Officer,

HARP

The ExOne Co. Reports Partnership With SSI To Drive Volume Production With Metal Binder Jetting, No Terms Disclosed

By Benzinga Newsdesk

Today, 3:34 PM

International supplier of high-performance metal products for automotive and industrial markets, SSI Sintered Specialties purchases X1 160Pro™ and InnoventPro® 3L metal 3D printers for production and is now

XONE

Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail

By Vandana Singh

Today, 3:34 PM

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Roche Holdings AG (OTC:RHHBY) announced positive data from Phase 2/3 2066 study of Ronapreve (casirivimab and imdevimab) or…

REGN